Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
V-0219
Cat. No.:
OB0425LY-134
Appearance:
Oil
Purity:
98.65%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
V-0219 is a highly active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator (PAM).
Synonyms:
878453-71-5; 4-[[1-[[3-[4-(Trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]piperidin-3-yl]methyl]morpholine; 4-{[1-({3-[4-(Trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)-3-piperidinyl]methyl}morpholine
CAS No.:
878453-71-5
Compound CID:
6486002
Formula:
C20H25F3N4O2
Formula Weight:
410.43
Specification
Target:
GLP receptor
Pathway:
GPCR/G protein
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
V-0219 plays a role in obesity-related diabetes research.
